





|  | 10D-   | CT    | (10D, 14D) |       | Risk ratio | Risk ratio         | Risk of bias                                      |  |
|--|--------|-------|------------|-------|------------|--------------------|---|--|
| Study of subgroup  | Events | Total | Events     | Total | Weight     | M-H, random, 95% C |   | ABCDEFG  |
| Ayse Kefeli et al. (2016)  | 113    | 118   | 114        | 121   | 21.2%      | 1.02 [0.96, 1.08]  | •   |  |
| Baysyigit et al. (2016)  | 98     | 126   | 46         | 69    | 4.5%       | 1.17 [0.96, 1.41]  | -   |  |
| Fracesco et al. (2018)   | 60     | 62    | 52         | 55    | 16.3%      | 1.02 [0.95, 1.11]  |   | $\oplus \oplus \oplus \oplus \oplus \oplus \oplus$   |
| Gungor et al. (2015)   | 72     | 86    | 62         | 80    | 6.7%       | 1.08 [0.93, 1.26]  | +   | $\oplus$ $\bigcirc$ $\bigcirc$ $\bigcirc$ $\bigcirc$ |
| Liou et al. (2016)   | 453    | 476   | 461        | 470   | 30.9%      | 0.97 [0.95, 0.99]  | •   | $\oplus \oplus \oplus \oplus \oplus \oplus \oplus$   |
| Zhou et al. (2015)   | 263    | 301   | 261        | 300   | 20.4%      | 1.00 [0.94, 1.07]  | •   | $\oplus \oplus \oplus \oplus \oplus \oplus \oplus$   |
| Total (95% CI)   |        | 1,169 |            | 1,095 | 100.0%     | 1.01 [0.97, 1.06]  |   |  |
| Total events   | 1,059  |       | 996        |       |            |                    | <del>                                      </del> | -  |
| Heterogeneity: Tau <sup>2</sup> =0.00; Chi <sup>2</sup> =12.10, df=5 (p=0.03); I <sup>2</sup> =59% |        |       |            |       |            |                    | 0.01 0.1 1 10 10                                  | 0  |
| Test for overall effect: Z=0.49 (p=0.62)   |        |       |            |       |            |                    | BQT 10 days-CT (10D, 14D)                         |  |



**Supplementary Figure 8.** Comparison between 10-day concomitant therapy and 10-/14-day bismuth quadruple therapy (A) intention-to-treat analysis (B) per protocol analysis Risk of bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); G, other bias. CT, concomitant therapy; BQT, bismuth quadruple therapy; M-H, Mantel-Haenszel; CI, confidence interval.